Proteomic Prediction of Clinical Benefit in HNSCC
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Head and Neck Cancer
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Enrollment
- 352
- Locations
- 3
- Primary Endpoint
- Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles
- Status
- Completed
- Last Updated
- 13 years ago
Overview
Brief Summary
RATIONALE: Studying samples of blood in the laboratory may help doctors learn more about cancer. It may also help doctors predict how well patients will respond to treatment.
PURPOSE: This research study is looking at proteins in blood samples to predict treatment benefit in patients with recurrent and/or metastatic squamous cell head and neck cancer.
Detailed Description
OBJECTIVES: * To identify head and neck squamous cell cancer patients who will benefit from treatment with the EGFR inhibitors (i.e., erlotinib hydrochloride, gefitinib, and cetuximab) and VEGF inhibitor (i.e., bevacizumab), based on predictive proteomic profiles in patient blood samples. OUTLINE: This is a multicenter study. Blood samples are analyzed for proteomic profile to determine good and bad prognoses in patients treated with or without EGFR inhibitors and/or a VEGF inhibitor.
Investigators
Barbara Murphy, MD
Professor of Medicine, Medical Oncologist
Vanderbilt-Ingram Cancer Center
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Identification of patients who will benefit from treatment with EGFR and/or VEGF inhibitors based on serum proteomic profiles
Time Frame: upon analysis of each patient tissue collection